The World Health Organization (WHO) today recommended another treatment for COVID-19, a monoclonal antibody combination from Regeneron already in use in the United States, though it urged companies and governments to make sure it's accessible to lower- and middle-income countries.Supply, drug administration challengesThe WHO's conditional recommendation for the monoclonal antibody cocktail, which consists of casirimivab and imdevimab, applies to patients with nonsevere COVID-19 who are at high risk for hospitalization and for people who have severe and critical infections who have no antibodies to SARS-COV-2.In November, the US Food and Drug Administration issued an emergency use authorization for the drug combination for adults and kids